Trade Summary

Yesterday, Van Houte Hans, serving as CFO at Nurix Therapeutics, Inc. (NRIX), sold 2,388 shares at $16.65 per share, for a total transaction value of $39,749.00. Following this transaction, Van Houte Hans now holds 51,647 shares of NRIX.

This sale represents a 4.00% decrease in Van Houte Hans's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Thursday, April 30, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, April 30, 2026, meaning the disclosure happened on the same day as the trade.

Nurix Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.